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Abstracts / Biol Blood Marrow Transplant 20 (2014) S27eS44 S33mismatched with the pt, fewer 10/10 donors and increased
4/6 or worse CBUs were used. API pts were more often
transplanted with an HLA mismatched source when the
source is also race/ethnic mismatched.
Conclusion: This study shows that AFA, API, CAU, and HIS
pts, transplanted in the past 5 years, most utilized a race/
matched donor. From 2008 to present, greater than 70% of
donors and greater than 50% of CBU transplants were race/
ethnic matched between the pt and cell source. In addition,
better HLA matching was observed when the pt and cell
source were matched for race/ethnicity.15
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Haploidentical hematopoietic stem cell transplantation us-
ing T-cell depleted grafts (haploHSCT) is an option for pedi-
atric patients with high-risk hematological malignancies
lacking an HLA-identical donor. Since December 2006 to
September 2013; 55 children underwent an haploHSCT using
CD3+/CD19+ depletion for graft manipulation. Eleven pa-
tients were in 1st CR, 22 in 2nd CR and 22were in>2nd CR at
time of transplantation. The conditionig regimen consisted of
30 mg/m2/d of i.v. ﬂudarabine on days -6 to -2, 3.2-4.8 mg/
kg/day of i.v. busulfan on days -6 and -4 and 5 mg/kg/day of
i.v. thiotepa on days -3 to -2. PBPC were mobilized and
collected in the standard manner. GvHD prophylaxis
included CsA 3mg/kg/day from day -1. Allografts contained a
median of 5.75 x106 CD34 cells/kg and 1.0 x 104 CD3 cells/kg.
Median times to neutrophil and platelet recovery were 13
and 10 days, respectively. The probability of aGvHD and
cGvHD were 135% and 3110% respectively. NRM was
145% by day +100 and 216% by 2 years after transplant.
Cause of dead were relapse in 9 cases, severe viral infections
in 7 and graft failure in 2. The probability of relapse was
298%. With a median follow-up of 24 months, the proba-
bility of DFS was 558%. On a multivariate analysis the fac-
tors that positive impact on DFS were age below 12 years
(HR;0.26, 95%CI: 0.09-0.79 p<0.009) and cGvHD (HR;0.68,
95%CI: 0.01-0.53 p<0.01). Our results suggest that hap-
loidentical donors are a good option for pediatric patients
with high-risk hematological malignancies who need an
allogeneic transplantation. Graft manipulation resulted on
low incidence of severe aGvHD. DFS was better for patients
with cGvHD mainly due to lower relapse incidence. Severe
viral infections is a relevant problem in the early phase after
transplantation.16
Donor Telomere Length Predicts Recipient Survival after
Allogeneic Hematopoietic Cell Transplantation in
Patients with Bone Marrow Failure Syndromes
Shahinaz Gadalla 1, Tao Wang 2, Michael Haagenson 3,
Stephen R. Spellman 4, Stephanie J. Lee 5, Kirsten M. Williams 6,
Jason Y. Wong 7, Immaculata De Vivo 7, Sharon A. Savage 8.
1Clinical Genetics Branch, National Cancer Institute, Rockville,
MD; 2CIBMTR and Division of Biostatistics, Medical College of
Wisconsin, Milwaukee, WI; 3CIBMTR, Minneapolis, MN;
4Immunobiology and Observational Research, Center forInternational Blood and Marrow Transplant Research,
Minneapolis, MN; 5CIBMTR and Clinical Research Division, Fred
Hutchinson Cancer Research Center, Seattle, WA; 6National
Cancer Institute, NIH, Bethesda, MD; 7Harvard School of Public
Health, Boston, MA; 8Clinical Genetics Branch, Division of
Cancer Epidemiology and Genetics, National Cancer Institute,
Bethesda, MD
Background: Telomeres are long nucleotide repeats and an
associated protein complex at chromosome ends essential
for chromosomal stability. They shorten with every cell di-
vision and thus are a marker of cellular replicative capacity.
We hypothesized that telomere length may be a predictive
marker for outcomes after hematopoietic cell trans-
plantation (HCT).
Method: We used quantitative PCR (qPCR) to measure pre-
transplant relative telomere length (RTL) in blood DNA of 342
young recipients (median age¼14 yr; range¼0.5e39) and
their matched unrelated donors (median age¼36 yr;
range¼19-61). HCTs were performed for marrow failure
syndromes between 1989 and 2007 and reported to the
Center for International Blood and Marrow Transplant
Research (CIBMTR), and the National MarrowDonor Program
(NMDP). The log-rank test was used to compare survival
across RTL categories. For multivariable models, we used Cox
proportional hazard models and calculated hazard ratios
(HR) and 95% conﬁdence intervals (CI) comparing outcome
across RTL categories.
Results: Patients were followed for up to 20 years
(median¼6.3 years; range¼0.5e20.7), with an overall sur-
vival (OS) probability at 3 years of 49% (44-55). There were
243 (71%) with severe aplastic anemia, 87 (25%) with Fanconi
anemia, and 12 (4%) with Diamond Blackfan anemia. Pre-
transplant RTL in the recipients was not associated with
post-transplant outcomes, including OS (3-year survival
probability¼51% and 46%, in RTL 25% percentile and <25th
percentile-for age, respectively; p¼0.76); acute (p¼0.53 at
100 days) or chronic GVHD (p¼0.99 at 1 year) and neutrophil
engraftment (p¼0.48). Pre-transplant donor RTL was a sig-
niﬁcant predictor for OS after HCT, with longer donor telo-
mere length associated with improved survival (3 year OS
59%, 49%, and 38%, in the longest, intermediate, and shortest
tertiles, respectively; p¼0.006). No association between
donor RTL and either acute or chronic GVHD or engraftment
was observed. Donor RTL was correlated with age (R2¼0.12,
p<0.0001), but after adjusting for donor age and factors
known to inﬂuence patient survival after HCT (such as prior
treatment and time between diagnosis and transplant),
